82 related articles for article (PubMed ID: 10805212)
41. Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processing.
Legge KL; Min B; Potter NT; Zaghouani H
J Exp Med; 1997 Mar; 185(6):1043-53. PubMed ID: 9091578
[TBL] [Abstract][Full Text] [Related]
42. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis.
Nicholson LB; Greer JM; Sobel RA; Lees MB; Kuchroo VK
Immunity; 1995 Oct; 3(4):397-405. PubMed ID: 7584131
[TBL] [Abstract][Full Text] [Related]
43. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.
Getts DR; Martin AJ; McCarthy DP; Terry RL; Hunter ZN; Yap WT; Getts MT; Pleiss M; Luo X; King NJ; Shea LD; Miller SD
Nat Biotechnol; 2012 Dec; 30(12):1217-24. PubMed ID: 23159881
[TBL] [Abstract][Full Text] [Related]
44. Administration of PLP139-151 primes T cells distinct from those spontaneously responsive in vitro to this antigen.
Penitente R; Nicolò C; Van den Elzen P; Di Sante G; Agrati C; Aloisi F; Sercarz EE; Ria F
J Immunol; 2008 May; 180(10):6611-22. PubMed ID: 18453580
[TBL] [Abstract][Full Text] [Related]
45. Pulmonary Administration of Soluble Antigen Arrays Is Superior to Antigen in Treatment of Experimental Autoimmune Encephalomyelitis.
Kuehl C; Thati S; Sullivan B; Sestak J; Thompson M; Siahaan T; Berkland C
J Pharm Sci; 2017 Nov; 106(11):3293-3302. PubMed ID: 28625726
[TBL] [Abstract][Full Text] [Related]
46. Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis.
Northrup L; Griffin JD; Christopher MA; Antunez LR; Hartwell BL; Pickens CJ; Berkland C
J Control Release; 2017 Nov; 266():156-165. PubMed ID: 28963036
[TBL] [Abstract][Full Text] [Related]
47. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis.
De Rosa V; Procaccini C; La Cava A; Chieffi P; Nicoletti GF; Fontana S; Zappacosta S; Matarese G
J Clin Invest; 2006 Feb; 116(2):447-55. PubMed ID: 16410832
[TBL] [Abstract][Full Text] [Related]
48. CD26/DP IV in T cell activation and autoimmunity.
Preller V; Gerber A; Togni M; Wrenger S; Schraven B; Röcken C; Marguet D; Ansorge S; Brocke S; Reinhold D
Adv Exp Med Biol; 2006; 575():187-93. PubMed ID: 16700522
[No Abstract] [Full Text] [Related]
49. Immunomodulators: particulate promotion of tolerance.
Tse MT
Nat Rev Drug Discov; 2013 Jan; 12(1):22-3. PubMed ID: 23237919
[No Abstract] [Full Text] [Related]
50. Regulation of experimental autoimmune encephalomyelitis by interleukin-12.
Leonard JP; Waldburger KE; Goldman SJ
Ann N Y Acad Sci; 1996 Oct; 795():216-26. PubMed ID: 8958933
[TBL] [Abstract][Full Text] [Related]
51. T cell activation status determines the cytokine pattern induced by zymosan and bacterial DNA both in thymocytes and splenocytes.
Zimmermann C; Weber A; Mausberg AK; Kieseier BC; Hartung HP; Hofstetter HH
Clin Exp Immunol; 2013 May; 172(2):245-53. PubMed ID: 23574321
[TBL] [Abstract][Full Text] [Related]
52. Self-peptide anaphylaxis.
Marshall H
Trends Immunol; 2001 May; 22(5):242. PubMed ID: 11323277
[No Abstract] [Full Text] [Related]
53. Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Cusick MF; Libbey JE; Trede NS; Fujinami RS
PLoS One; 2014; 9(4):e94486. PubMed ID: 24718491
[TBL] [Abstract][Full Text] [Related]
54. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells.
Mathisen PM; Yu M; Johnson JM; Drazba JA; Tuohy VK
J Exp Med; 1997 Jul; 186(1):159-64. PubMed ID: 9207010
[TBL] [Abstract][Full Text] [Related]
55. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity.
Lundström W; Highfill S; Walsh ST; Beq S; Morse E; Kockum I; Alfredsson L; Olsson T; Hillert J; Mackall CL
Proc Natl Acad Sci U S A; 2013 May; 110(19):E1761-70. PubMed ID: 23610432
[TBL] [Abstract][Full Text] [Related]
56. Empirical modeling of T cell activation predicts interplay of host cytokines and bacterial indole.
Steinmeyer S; Howsmon DP; Alaniz RC; Hahn J; Jayaraman A
Biotechnol Bioeng; 2017 Nov; 114(11):2660-2667. PubMed ID: 28667749
[TBL] [Abstract][Full Text] [Related]
57. Cytokines as intrinsic and exogenous regulators of pathogenesis in experimental autoimmune encephalomyelitis.
Begolka WS; Miller SD
Res Immunol; 1998; 149(9):771-81; discussion 843-4, 855-60. PubMed ID: 9923632
[No Abstract] [Full Text] [Related]
58. Adoptive Transfer of Regulatory T Cells as a Promising Immunotherapy for the Treatment of Multiple Sclerosis.
Duffy SS; Keating BA; Moalem-Taylor G
Front Neurosci; 2019; 13():1107. PubMed ID: 31680840
[No Abstract] [Full Text] [Related]
59. B lymphocyte stimulator and autoimmune disease.
Wardle EN
Saudi J Kidney Dis Transpl; 2004; 15(2):155-6. PubMed ID: 17642768
[No Abstract] [Full Text] [Related]
60. Antisense modulation of IL7R splicing to control sIL7R expression in human CD4
Galarza-Muñoz G; Kennedy-Boone D; Schott G; Bradrick SS; Garcia-Blanco MA
RNA; 2022 Aug; 28(8):1058-1073. PubMed ID: 35613883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
